journal article·2020-10-26Open access

Chitosan-Based Delivery Systems Loaded with Glibenclamide and Lipoic Acid: Formulation, Characterization, and Kinetic Release Studies

Luminita-Georgeta Confederat, Iuliana Motrescu, Mihaela Iustina Condurache, Sandra Constantin, Alexandra Bujor, Cristina Gabriela Tuchilus, Lenuta Profire

Applied Sciences· Volume 10· Issue 21

Abstract

Glibenclamide and lipoic acid are two drugs frequently recommended for the management of diabetes mellitus, and so, the development of a new formulation containing both substances has a great benefit in terms of efficiency and compliance, acting also as a multi-target drug system. Accordingly, the aim of this study was the formulation and physicochemicalcharacterization of new polymeric systems based on chitosan (CS) in whose matrix were encapsulated glibenclamide (Gly) and lipoic acid (LA). The polymeric systems were prepared as microparticles (CS–Gly, CS–LA, and CS–Gly–LA) through ionic gelation method, using pentasodium tripolyphosphate (TPP) as crosslinking agent. The polymeric systems obtained were characterized in terms of particle size and morphology, IR spectroscopy, entrapment efficiency and drug loading, swelling degree, and therelease of the active substances from the chitosan matrix. The polymeric systems obtained were stable systems; the presence of glibenclamide and lipoic acid into the polymer matrix were proved by IR spectroscopy. The entrapment efficiency was 94.66% for Gly and 39.68% for LA. The developed polymeric systems proved a favorable swelling degree and drug release profile, the percentage of release being 88.68% for LA and 75.17% for Gly from CS–Gly–LA systems.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Biochemical Acid Research Studies · biodegradable polymer synthesis and properties · Carbon dioxide utilization in catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Microbiology, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania

Department of Exact Sciences, “Ion Ionescu de la Brad” University of Agricultural Sciences and Veterinary Medicine, 700490 Iași, Romania

Department of Biomedical Sciences, “Grigore T. Popa” University of Medicine and Pharmacyof Iasi, 700115 Iasi, Romania

Department of Pharmaceutical Chemistry, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania

Department of Pharmaceutical Technology, “Grigore T. Popa” University of Medicine and Pharmacy of Iasi, 700115 Iasi, Romania

Funding

AUF-IFA 2019-2020 · L’ORÉAL-UNESCO through the fellowship program “For women in science”

References (43)

Show source-provided references
1. Delivery and organization of diabetes care: Integrated care10.1016/j.mpmed.2018.11.008 ↗
2. Antidiabetic effects and safety profile of chitosan delivery systems loaded with new xanthine-thiazolidine-4-one derivatives: Invivo studies10.1016/j.jddst.2020.102091 ↗
3. Factors associated with therapeutic target achievement in the control of complications in consequence of diabetes: A hospital-based study in west of Iran10.1016/j.dsx.2019.04.031 ↗
4. Frequency and pattern of chronic complications of diabetes and their association with glycemic control10.1016/j.dsx.2017.03.007 ↗
5. Microvascular complications in diabetes: A growing concern for cardiologists10.1016/j.ijcard.2019.02.030 ↗
6. Microvascular Complications of Diabetes: What’s Relevant for Practice?10.1016/j.nurpra.2016.08.012 ↗
7. Foot complications in patients with diabetes
8. Macrovascular disease in diabetes10.1383/medc.2006.34.3.101 ↗
9. Macrovasculardisease: Pathogenesis and risk assessment10.1016/j.mpmed.2014.10.012 ↗
10. The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations10.1016/j.ejps.2018.10.015 ↗
11. The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, α-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2)10.1016/j.bioorg.2019.02.009 ↗
12. Type II diabetes mellitus: A review on recent drug based therapeutics10.1016/j.biopha.2020.110708 ↗
13. Treating diabetes today: A matter of selectivity of sulphonylureas10.1111/j.1463-1326.2011.01507.x ↗
14. Sulfonylureas: A new look at old therapy10.1007/s11892-014-0473-5 ↗
15. Chitosan microparticles loaded with antidiabetic drugs—Preparation and characterization
16. Strategies to improve glibenclamide dissolution: A review using database tomography
17. Molecular pathways associated with oxidative stress in diabetes mellitus10.1016/j.biopha.2018.09.058 ↗
18. Diabetes mellitus and oxidative stress—A concise review10.1016/j.jsps.2015.03.013 ↗
19. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis10.1016/j.redox.2018.09.025 ↗
20. The research and development on the antioxidants in prevention of diabetic complications10.1016/j.apjtm.2016.07.001 ↗
21. Lipoic acid—Biological activity and therapeutic potential10.1016/S1734-1140(11)70600-4 ↗
22. Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential10.1016/j.bbagen.2009.07.026 ↗
23. Diabetes and alpha lipoic acid10.3389/fphar.2011.00069 ↗
24. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases10.1186/1758-5996-6-80 ↗
25. Classification, pathophysiology, diagnosis and management of diabetes mellitus10.4172/2155-6156.1000541 ↗
26. Potential of chitosan and its derivatives for controlled drug release applications—A review10.1016/j.jddst.2018.10.020 ↗
27. Responsive polymeric delivery systems10.1016/S0169-409X(00)00136-8 ↗
28. Pharmaceutical applications of chitosan10.1016/j.cis.2018.11.008 ↗
29. Formulation and characterization of new polymeric systems based on chitosan and xanthine derivatives with thiazolidine-4-one scaffold10.3390/ma12040558 ↗
30. Development and optimization of ezetimib nanoparticles with improved antihyperlipidemic activity10.1016/j.jddst.2018.12.001 ↗
31. Biological evaluation of chitosan-antidiabetic drug formulations for the treatment of diabetes mellitus
32. Chitosan-based nanoparticles: An overview of biomedical applications and its preparation10.1016/j.jddst.2018.10.022 ↗
33. Biopolymers with medical applications – Optimized method for obtaining chitosan-based delivery systems10.37358/RC.18.7.6411 ↗
34. Novel self-assembled core-shell nanoparticles based on crystalline amorphous moieties of aliphatic polyesters for efficient controlled drug release10.1016/j.jconrel.2009.05.013 ↗
35. Development and Validation of RP-HPLC method for estimation of Gliclazide in bulk and tablet dosage form
36. A simple and specific method for estimation of lipoic acid in human plasma by high performance liquid chromatography
37. Characterization and anti-tumour effects of chondroitin sulphate—Chitosan nanoparticles delivery systems10.1007/s11051-014-2672-z ↗
38. Chitosan/Casein microparticles: Preparation, characterization and drug release studies
39. Development, optimization and biological evaluation of chitosan scaffold formulations of new xanthine derivatives for treatment of type 2 diabetes mellitus10.1016/j.ejps.2015.06.008 ↗
40. Chitosan—A versatile semi-synthetic polymer in biomedical applications10.1016/j.progpolymsci.2011.02.001 ↗
41. In vitro and in vivo theophylline release from cellulose/chondroitin sulphate hydrogels10.1016/j.carbpol.2012.05.004 ↗
42. Design and development of gliclazidemucoadhesivemicrocapsules: In vitro and in vivo evaluation10.1208/s12249-008-9041-0 ↗
43. Evolution of dissolution media over the last twenty years10.14227/DT210314P6 ↗